Real-time image-guided direct convective perfusion of intrinsic brainstem lesions. Technical note.
暂无分享,去创建一个
John A Butman | Deric M. Park | Katherine E Warren | Zenaide Quezado | R. Brady | E. Oldfield | J. Butman | R. Lonser | Z. Quezado | M. Walker | K. Warren | D. Croteau | Edward H Oldfield | Roscoe O Brady | R Aaron Robison | Russell R Lonser | David Croteau | S. Walbridge | Stuart Walbridge | Raphael Schiffman | Marsha Merrill | Marion L Walker | Deric M Park | M. Merrill | R. Schiffman | R. A. Robison | R. Brady
[1] E. Oldfield,et al. Chronic interstitial infusion of protein to primate brain: determination of drug distribution and clearance with single-photon emission computerized tomography imaging. , 1997, Journal of neurosurgery.
[2] Barry W Wessels,et al. Safety and Feasibility of Convection-enhanced Delivery of Cotara for the Treatment of Malignant Glioma: Initial Experience in 51 Patients , 2005, Neurosurgery.
[3] R. Brady,et al. Therapy for the sphingolipidoses. , 1998, Archives of neurology.
[4] G J Murray,et al. Image-guided, direct convective delivery of glucocerebrosidase for neuronopathic Gaucher disease , 2007, Neurology.
[5] R. Puri,et al. Mutation and functional analysis of IL-13 receptors in human malignant glioma cells. , 2001, Oncology research.
[6] D. Hargrave,et al. Diffuse brainstem glioma in children: critical review of clinical trials. , 2006, The Lancet. Oncology.
[7] J. Dambrosia,et al. Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher's disease. , 1991, The New England journal of medicine.
[8] Stephan E Maier,et al. Pretreatment prediction of brain tumors' response to radiation therapy using high b-value diffusion-weighted MRI. , 2004, Neoplasia.
[9] R. Puri,et al. Preclinical studies with IL-13PE38QQR for therapy of malignant glioma. , 2000, Drug news & perspectives.
[10] R. Brady,et al. Replacement therapy for inherited enzyme deficiency. Use of purified glucocerebrosidase in Gaucher's disease. , 1974, The New England journal of medicine.
[11] M. Verity,et al. Infantile Gaucher's disease: neuropathology, acid hydrolase activities and negative staining observations. , 1977, Neuropadiatrie.
[12] M. Berger,et al. Comparison of intratumoral bolus injection and convection-enhanced delivery of radiolabeled antitenascin monoclonal antibodies. , 2006, Neurosurgical focus.
[13] S. Kunwar. Convection enhanced delivery of IL13-PE38QQR for treatment of recurrent malignant glioma: presentation of interim findings from ongoing phase 1 studies. , 2003, Acta neurochirurgica. Supplement.
[14] R Langer,et al. New methods of drug delivery. , 1990, Science.
[15] R. Schiffmann,et al. The efficacy of enzyme replacement therapy in patients with chronic neuronopathic Gaucher's disease. , 2001, The Journal of pediatrics.
[16] S. Gebarski,et al. Stereotaxic biopsy of intrinsic lesions of the brain stem. , 1986, Journal of neurosurgery.
[17] E. Oldfield,et al. Convective delivery of macromolecules into the naive and traumatized spinal cords of rats. , 1999, Journal of neurosurgery.
[18] W. Pardridge,et al. Drug Delivery to the Brain , 1997, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[19] John A Butman,et al. Successful and safe perfusion of the primate brainstem: in vivo magnetic resonance imaging of macromolecular distribution during infusion. , 2002, Journal of neurosurgery.
[20] C. Patlak,et al. Intrathecal chemotherapy: brain tissue profiles after ventriculocisternal perfusion. , 1975, The Journal of pharmacology and experimental therapeutics.
[21] P F Morrison,et al. Variables affecting convection-enhanced delivery to the striatum: a systematic examination of rate of infusion, cannula size, infusate concentration, and tissue-cannula sealing time. , 1999, Journal of neurosurgery.
[22] R. Puri,et al. IL-13 Receptor-Targeted Cytotoxin Cancer Therapy Leads to Complete Eradication of Tumors with the Aid of Phagocytic Cells in Nude Mice Model of Human Cancer1 , 2002, The Journal of Immunology.
[23] R. Puri,et al. Intratumor administration of interleukin 13 receptor-targeted cytotoxin induces apoptotic cell death in human malignant glioma tumor xenografts. , 2002, Molecular cancer therapeutics.
[24] P F Morrison,et al. Focal delivery during direct infusion to brain: role of flow rate, catheter diameter, and tissue mechanics. , 1999, American journal of physiology. Regulatory, integrative and comparative physiology.
[25] I. Pastan,et al. Human glioma cells overexpress receptors for interleukin 13 and are extremely sensitive to a novel chimeric protein composed of interleukin 13 and pseudomonas exotoxin. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.
[26] P F Morrison,et al. Convection-enhanced delivery of macromolecules in the brain. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[27] R. Puri,et al. Interleukin‐13 receptor as a unique target for anti‐glioblastoma therapy , 2001, International journal of cancer.
[28] P F Morrison,et al. Convection-enhanced distribution of large molecules in gray matter during interstitial drug infusion. , 1995, Journal of neurosurgery.
[29] C. Mignot,et al. Type 2 Gaucher disease: 15 new cases and review of the literature , 2006, Brain and Development.
[30] A. Vortmeyer,et al. Real-time in vivo imaging of the convective distribution of a low-molecular-weight tracer. , 2005, Journal of neurosurgery.
[31] E. Oldfield,et al. Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors , 1997, Nature Medicine.
[32] E. Oldfield,et al. Direct convective delivery of macromolecules to the spinal cord. , 1998, Journal of neurosurgery.
[33] M. Brechbiel,et al. Real-time, Image-Guided, Convection-Enhanced Delivery of Interleukin 13 Bound to Pseudomonas Exotoxin , 2006, Clinical Cancer Research.
[34] S. Donaldson,et al. Advances toward an understanding of brainstem gliomas. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] P. Kaplan,et al. Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. , 2002, The American journal of medicine.